Weekly Investment Analysts’ Ratings Changes for Sionna Therapeutics (SION)

by · The Markets Daily

Several analysts have recently updated their ratings and price targets for Sionna Therapeutics (NASDAQ: SION):

  • 12/29/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/23/2025 – Sionna Therapeutics is now covered by analysts at Lifesci Capital. They set an “outperform” rating and a $60.00 price target on the stock.
  • 12/22/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/15/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/13/2025 – Sionna Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
  • 12/8/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/1/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/1/2025 – Sionna Therapeutics had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.
  • 11/25/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/19/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/19/2025 – Sionna Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $50.00 price target on the stock.
  • 11/18/2025 – Sionna Therapeutics was upgraded by analysts at BTIG Research to a “strong-buy” rating.
  • 11/15/2025 – Sionna Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
  • 11/13/2025 – Sionna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/5/2025 – Sionna Therapeutics had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc..

Insider Activity

In other news, Director Peter A. Thompson sold 33,356 shares of the business’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the transaction, the director owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Orbimed Advisors Llc sold 33,356 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the transaction, the director directly owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. The trade was a 0.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 1,571,610 shares of company stock valued at $58,355,629. Insiders own 3.90% of the company’s stock.

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

See Also